Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 May 12;12:3343–3352. doi: 10.2147/CMAR.S250772

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Lin et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Expression pattern and clinical significance of miR-340 in GBM samples. (A) miR-340 was significantly up-regulated in the Proneural subtype (PN) compared with the other subtypes: Classical (CL), Mesenchymal (ME) and Neural (NE) in TCGA dataset. (B) EMT process associated genes were more enriched in the GBM patients with low expression level of miR-340 via GSEA analysis in TCGA dataset. (C) High level of miR-340 predicts a better prognosis in TCGA GBM patients. (D) The expression level of miR-340 was lower in recurrent GBM than those in primary cases. (E) miR-340 was significantly down-regulated in GBM cells (U87, U251 and LN229 cell lines) compared to normal glial cell line (NHA). * P <0.05, **P<0.01.